Dx™ Pcr Platform To Support Submission To The U.S. FDA
18/11/2025 14:24
Co-Diagnostics Inc CODX.O: CO-DIAGNOSTICS INITIATES CLINICAL EVALUATIONS FOR UPPER RESPIRATORY MULTIPLEX POINT-OF-CARE TEST ON CO-DX™ PCR PLATFORM TO SUPPORT SUBMISSION TO THE U.S. FDA Source text: ID:nPn18GhMta Further company coverage: CODX.O
Recent news on Co-Diagnostics
See all newsDiagnostics' Joint Venture Cosara Diagnostics Announces Publication Of Peer-Reviewed Hpv Screening Study Using Cosara's Saragene® Test
Diagnostics - Cosara To Initiate Sales Activities Across India And South Asia
Diagnostics’ Brian Brown Stepped Down As CFO Effective September 2
Diagnostics Q2 revenue rises slightly amid international expansion
Diagnostics - Amends Equity Distribution Agreement With Maxim Group For Common Stock Sale - SEC Filing